Myriad Genetics (MYGN)
(Real Time Quote from BATS)
$23.56 USD
+0.49 (2.12%)
Updated Oct 11, 2024 12:36 PM ET
2-Buy of 5 2
D Value A Growth C Momentum B VGM
Price, Consensus and EPS Surprise
MYGN 23.56 +0.49(2.12%)
Will MYGN be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for MYGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MYGN
MYGN Taps Ultima Genomics' UG 100 Platform for Advanced Clinical Tests
EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening
MYGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
BMRN or MYGN: Which Is the Better Value Stock Right Now?
Here's Why Myriad Genetics (MYGN) is a Strong Momentum Stock
Should You Continue to Retain MYGN Stock in Your Portfolio?
Other News for MYGN
Scotiabank Keeps Their Buy Rating on Myriad Genetics (MYGN)
Steady Growth and Market Stability Justify Hold Rating for Myriad Genetics
Myriad Genetics: Strategic Growth and Raised Price Target Reinforce Outperform Rating
Myriad Genetics: A Buy Rating Amid Reaffirmed Strategy and Growth Potential
Myriad Genetics: Assessing Sustainability of Revenue Growth Amid Market Challenges